Grail Inc (GRAL)
GRAIL, Inc. is a commercial-stage healthcare company focused on multi-cancer early detection testing and related services in the United States and international markets. Its commercial portfolio includes Galleri, a screening test designed for asymptomatic individuals over 50, as well as a diagnostic aid intended to help speed up diagnostic resolution for patients with clinical signs suggesting cancer. The company also provides development services that support clinical studies, pilot programs, research activities, and therapy development. In addition, GRAIL maintains a precision oncology portfolio built around an RUO-targeted methylation-based platform used in applications such as disease prognostication, risk stratification, minimal residual disease detection, and monitoring for recurrence and relapse. Founded in 2015, the company is headquartered in Menlo Park, California. The listed security is common stock on NASDAQ under the symbol GRAL.
Jump between the core stock analysis sections, valuation data, fair value models, technical outlook, and FAQ.
| Ticker | Fair Value | Fair Value Upside/Downside | Fair Value Rating | Analyst Price Target | Analyst Target Upside/Downside | Analyst Target Rating | Overall Financial Health | Upcoming Dividend Ex-Date | Dividend Payment Date | Upcoming Dividend | Dividend Yield | Next Earnings Date | P/E Ratio | Price-to-Book Ratio | Price-to-Sales Ratio | Market Cap | Enterprise Value | Total Debt / Total Capital | Free Float / Shares Outstanding | Altman Z-Score | Payout Ratio | Free Cash Flow / Net Income |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
NASDAQ-GRAL
|
$54.18
|
-23.6% Downside
|
Overvalued
|
$70.13
|
-1.2% Downside
|
Fair
|
Good
|
—
|
—
|
—
|
0.0%
|
August 18, 2026
|
-7.8x
|
1.2x
|
19.6x
|
2.957 B
|
2.292 B
|
1.7%
|
77.9%
|
-9.3
|
—
|
73.9%
|
